Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond Binary-The Case for Amyloid Centiloid Quantification.

JAMA·2026
Same author

Designing Consent Processes for Research With Older Adults Who May Lack Decisional Capacity: A Guide for Investigators.

Journal of the American Geriatrics Society·2026
Same author

Four Common Beliefs About Patient Memory Evaluations: Who Has Them and What Modifies Them?

American journal of Alzheimer's disease and other dementias·2026
Same author

Steroids, stress, and body mass index interact to accelerate female pubertal development.

The Journal of clinical endocrinology and metabolism·2026
Same author

Expert consensus on communicating tau PET results to persons living with MCI or dementia: Findings from a modified Delphi study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Qualitative insights into participant and care partner perspectives on research-based Alzheimer's disease biomarker testing and disclosure.

Journal of Alzheimer's disease reports·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Correlates and predictors of self-efficacy among dementia caregivers: D-CARE findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Primary cilia-extracellular vesicle crosstalk in Alzheimer's disease: Emerging mechanisms and biomarker potential.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Claire M Erickson1, Kristin Harkins2, Elisabeth Wood3

  • 1Banner Alzheimer's Institute, Phoenix, AZ, USA.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 24, 2025
PubMed
Summary
This summary is machine-generated.

New Alzheimer's disease (AD) blood tests like plasma pTau-217 are coming. This study tests eHealth platforms versus telehealth for returning AD biomarker results, assessing comprehension and psychological impact.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Area of Science:

  • Neurology
  • Biomarkers
  • Genetics

Background:

  • Alzheimer's disease (AD) blood biomarkers are increasingly vital for diagnosis, management, and clinical trial eligibility.
  • Current practices for returning biomarker results primarily focus on trial eligibility, not AD risks or treatment side effects.
  • Developing effective communication methods for AD blood biomarker results is crucial due to their growing utility.

Purpose of the Study:

  • To evaluate self-directed, scalable eHealth platforms versus telehealth for communicating Alzheimer's disease (AD) biomarker results (APOE and plasma pTau-217).
  • To assess participant comprehension, psychological impact, and experiences with different result disclosure methods.

Main Methods:

  • The decentralized, randomized eSMARTER trial enrolled ~600 adults aged 60-80 in the US.
  • Participants were randomized to receive APOE and plasma pTau-217 results via telehealth videoconference or a self-directed eHealth platform.
  • Educational and disclosure materials were developed for AD, pTau-217, and potential results (negative, intermediate, positive).

Main Results:

  • Data collection is ongoing, with assessments at seven days and four weeks post-disclosure.
  • Key metrics include result comprehension, psychological impact of learning pTau-217 information, and user experience with the eHealth platform.

Conclusions:

  • Disclosing AD biomarker status is becoming more common with new therapies and regulatory mandates (21st Century Cures Act).
  • There is a pressing need for scalable result return methods due to shortages in genetic counselors and dementia specialists.
  • The eSMARTER study will provide insights into the benefits and limitations of remote pTau-217 result disclosure, guiding future research on returning multiple biomarkers.